Ingenuity formalizes biomarker initiative backed by quantifiable results
Redwood City, CA– MAY 9, 2006 – Ingenuity Systems launches its biomarker workflow guide to formalize its ongoing biomarker initiative. Scientists will be able to utilize IPA to identify potentially useful biomarkers during the preclinical exploratory phase via analysis of gene expression array data or proteomics data.
With the workflow guide, researchers can more easily prioritize biomarker leads by associating them with biology relevant to the observed phenotype. IPA can also help researchers select biomarker panels from the most significant clusters by grouping clusters in the context of pathways, functions or diseases.
“We were able to use IPA’s computational pathways analytics to develop network signatures from gene expression data and to identify a novel biomarker candidate for Mesothelioma,” stated Dr. Harvey Pass, Professor of Cardiothoracic Surgery and Chief, Division of Thoracic Surgery and Thoracic Oncology at New York University. “Once we identify such biomarker candidates, we can look at larger cohorts of patients for further validation. We believe this Ingenuity methodology, which was used to find Osteopontin as a Mesothelioma marker as described in the New England Journal of Medicine, will become a standard protocol for biomarker discovery.”
IPA is a software application that enables researchers to model, analyze and understand the complex biological systems at the core of life science research. IPA is deployed in most major pharmaceutical companies and hundreds of biotechnology companies and academic institutions globally. It supports analysis of all high throughput analysis platforms and is used in virtually all areas of drug discovery and development from target identification and validation to biomarkers, predictive toxicology, and pharmacogenomics.
IPA is available as a web-delivered, hosted, or deployed solution. Fully functional complimentary trials are available at www.ingenuity.com/trial/start.html.
About Ingenuity Systems®
Ingenuity enables researchers to model, analyze and understand complex biological systems foundational to human health and disease. The Ingenuity products include pathways analysis software and knowledge bases for biologists and bioinformaticians, and enterprise knowledge management infrastructure, content and services for leading pharmaceutical and biotech companies. Ingenuity was founded in 1998 and is headquartered in Redwood City, California with offices in Germany, Switzerland, France, the United Kingdom, and Japan. www.ingenuity.com.